Phase 1 Leukaemia Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been newly diagnosed (with no prior treatment) with a specific type of blood cancer called B-precursor acute lymphoblastic leukemia (ALL), confirmed by standard testing.
• People whose leukemia has a specific genetic pattern called "Ph-like," identified through a special laboratory test called an LDA card.
• People whose leukemia has specific genetic changes affecting a pathway in the body called the JAK pathway — this includes certain gene rearrangements, fusions, deletions, or mutations (confirm specific details with trial site).
• People who have already completed a standard four-drug chemotherapy starting treatment (induction), which includes chemotherapy given into the spinal fluid, before beginning the trial drug ruxolitinib.
• People whose only prior treatment for this leukemia was emergency treatment such as steroids or hydroxyurea for serious complications, or a blood-filtering procedure to reduce white blood cell counts — no other prior leukemia treatment is permitted.
• People aged 18 years old up to (but not including) 40 years old.
• People who are reasonably physically functional, as measured by a standard medical scoring system (ECOG score of 2 or lower, or Karnofsky score of 60% or higher).
• People with a platelet count above 25,000 per microliter of blood.
• People whose liver and kidney function fall within acceptable ranges as measured by standard blood tests (confirm specific values with trial site).
• People who are willing and able to use reliable contraception (hormonal or barrier methods, or abstinence) throughout the study, because the drugs used may harm an unborn baby — this applies to both women who could become pregnant and men.
• People who are able to understand the study and are willing to sign a written consent form.

Who may not be able to join:

• People who are currently taking part in another clinical trial involving an experimental treatment.
• People who currently have a second cancer, unless they have finished treatment for it and have been cancer-free for 3 or more years (non-melanoma skin cancers are an exception).
• People who have had a serious allergic reaction to ruxolitinib or to medicines with a similar chemical makeup to drugs used in this study.
• People who have taken certain strong medications that affect how the body processes drugs (known as potent CYP3A4 inhibitors or inducers — examples include ketoconazole, voriconazole, clarithromycin, and itraconazole) within a certain timeframe before the trial drug begins (confirm timing with trial site). Note: fluconazole at the dose used in this study is allowed.
• People with serious uncontrolled health conditions, such as active infection, unstable heart problems, irregular heart rhythm, or mental health or personal circumstances that would make it difficult to follow the study requirements.
• People who are pregnant, as the trial drug ruxolitinib may harm an unborn baby.
• People who are breastfeeding, as the trial drug may pose risks to a nursing infant.
• People with Down Syndrome, due to a higher risk of serious side effects from the treatment.
• People whose leukemia is classified as Burkitt type leukemia.
• People who have a specific genetic abnormality in their leukemia called Philadelphia chromosome positive (Ph+) ALL at the time of diagnosis.

Important: Always verify eligibility with the trial site directly before applying.